Abstract
We have been developing synthetic gene promoters responsive to clinical doses of ionizing radiation (IR) for use in suicide gene therapy vectors. The crucial DNA sequences utilized are units with the consensus motif CC(A/T)6GG, known as CArG elements, derived from the IR-responsive Egr1 gene. In this study we have investigated the parameters needed to enhance promoter activation to radiation. A series of plasmid vectors containing different enhancer/promoters were constructed, transiently transfected into tumor cells (MCF-7 breast adenocarcinoma and U-373MG glioblastoma) and expression of a downstream reporter assayed. Results revealed that increasing the number of CArG elements, up to a certain level, increased promoter radiation-response; from a fold-induction of 1.95 ± 0.17 for four elements to 2.74 ± 0.17 for nine CArGs of the same sequence (for MCF-7 cells). Specific alteration of the core A/T sequences caused an even greater positive response, with fold-inductions of 1.71 ± 0.23 for six elements of prototype sequence compared with 2.96 ± 0.52 for one of the new sequences following irradiation. Alteration of spacing (from six to 18 nucleotides) between elements had little effect, as did the addition of an adjacent Sp1 binding site. Combining the optimum number and sequence of CArG elements in an additional enhancer was found to produce the best IR induction levels. Furthermore, the improved enhancers also performed better than the previously reported prototype when used in in vitro and in vivo experimental GDEPT. We envisage such enhancers will be used to drive suicide gene expression from vectors delivered to a tumor within an irradiated field. The modest, but tight expression described in the present study could be amplified using a molecular ‘switch’ system as previously described using Cre/LoxP. In combination with targeted delivery, this strategy has great potential for significantly improving the efficacy of cancer treatment in the large number of cases where radiotherapy is currently employed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Datta R et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements Proc Natl Acad Sci USA 1992 89: 10149–10153
Weichselbaum RR et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells Cancer Res 1994 54: 4266–4269
Joki T, Nakamura M, Ohno T . Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir Hum Gene Ther 1995 6: 1507–1513
Worthington J et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter Gene Therapy 2000 7: 1126–1131
Nuyts S et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation Gene Therapy 2001 8: 1197–1201
Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy Gene Therapy 2000 7: 511–517
Treisman R . The SRE: a growth factor responsive transcriptional regulator Semin Cancer Biol 1990 1: 47–58
Christy B, Nathans D . Functional serum response elements upstream of the growth factor-inducible gene zif268 Mol Cell Biol 1989 9: 4889–4895
Shaw PE, Schroter H, Nordheim A . The ability of a ternary complex to form over the serum response element correlates with serum inducibility of the human c-fos promoter Cell 1989 56: 563–572
Dalton S, Treisman R . Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element Cell 1992 68: 597–612
Hill CS et al. Functional analysis of a growth factor-responsive transcription factor complex Cell 1993 73: 395–406
Lim CP, Jain N, Cao X . Stress-induced immediate–early gene, egr-1, involves activation of p38/JNK1 Oncogene 1998 16: 2915–2926
Meyer RG, Kupper JH, Kandolf R, Rodemann HP . Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro Eur J Biochem 2002 269: 337–346
Hallahan DE et al. Spatial and temporal control of gene therapy using ionizing radiation Nat Med 1995 1: 786–791
Seung LP et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents Cancer Res 1995 55: 5561–5565
Staba MJ et al. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft Gene Therapy 1998 5: 293–300
Kawashita Y et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation Hum Gene Ther 1999 10: 1509–1519
Sakamoto KM . 5’ upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8 Oncogene 1991 6: 867–871
Spencer JA, Misra RP . Expression of the serum response factor gene is regulated by serum response factor binding sites J Biol Chem 1996 271: 16535–16543
Schwachtgen JL, Campbell CJ, Braddock M . Full promoter sequence of human early growth response factor-1 (Egr-1): demonstration of a fifth functional serum response element DNA Seq 2000 10: 429–432
Prywes R, Roeder RG . Purification of the c-fos enhancer-binding protein Mol Cell Biol 1987 7: 3482–3489
Spencer JA, Misra RP . Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated- mechanism in response to serum growth signals Oncogene 1999 18: 7319–7327
Kokoris MS, Sabo P, Adman ET, Black ME . Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant Gene Therapy 1999 6: 1415–1426
Datta R et al. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation Proc Natl Acad Sci USA 1993 90: 2419–2422
Treisman R . Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors Cell 1986 46: 567–574
Pellegrini L, Tan S, Richmond TJ . Structure of serum response factor core bound to DNA Nature 1995 376: 490–498
Ruan H et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy Neoplasia 2001 3: 255–263
Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes Int J Radiat Oncol Biol Phys 1998 42: 913–916
Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes Greco O et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy 2002 (in press).
Pollock R, Treisman R . A sensitive method for the determination of protein-DNA binding specificities Nucleic Acids Res 1990 18: 6197–6204
Treisman R, Marais R, Wynne J . Spatial flexibility in ternary complexes between SRF and its accessory proteins EMBO J 1992 11: 4631–4640
Scott SD et al. A radiation-controlled molecular switch for use in gene therapy of cancer Gene Therapy 2000 7: 1121–1125
Kjellen E et al. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments Radiother Oncol 1991 22: 81–91
Acknowledgements
The work described in this study was initiated at the Gray Cancer Institute, Northwood, Middlesex, UK, while funded by the Gray Laboratory Cancer Research Trust and the Cancer Research Campaign (CRC project grants SP2490/0101 and SP2500/0101). The authors would also like to thank Mrs Sara Bourne, Ms Amanda Walker, Mr Peter Boulton and Mrs Barbara Joiner for their excellent technical support.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, S., Joiner, M. & Marples, B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 9, 1396–1402 (2002). https://doi.org/10.1038/sj.gt.3301822
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301822
Keywords
This article is cited by
-
Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs
Clinical and Translational Medicine (2017)
-
Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging
Molecular Imaging and Biology (2015)
-
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation
Tumor Biology (2015)
-
Regulation of gene expression in prostate cancer cells with an artificially constructed promoter responsive to radiation
Gene Therapy (2012)
-
An experimental study on cervix cancer with combination of HSV-TK/GCV suicide gene therapy system and 60Co radiotherapy
BMC Cancer (2010)